Related Experiment Videos
Biphenyls as potent vitronectin receptor antagonists
Klaus Urbahns1, Michael Härter, Markus Albers
1Institute of Medicinal Chemistry, Pharma Research Centre, Bayer AG, D-42096 Wuppertal, FRG. klaus.urbahns.ku1@bayer.co.jp
Bioorganic & Medicinal Chemistry Letters
|January 5, 2002
Summary
Vitronectin receptor antagonists show promise for treating restenosis after angioplasty. Researchers identified potent compounds targeting alpha(V)beta(3) and GPIIbIIIa receptors, inhibiting smooth muscle cell migration.
Area of Science:
- Pharmacology
- Cardiovascular Research
- Medicinal Chemistry
Background:
- Restenosis after balloon angioplasty is a significant clinical challenge.
- Vitronectin receptor (alpha(V)beta(3)) antagonism is a potential therapeutic strategy.
- Targeting smooth muscle cell migration is crucial for preventing restenosis.
Purpose of the Study:
- To screen a focused combinatorial library for novel vitronectin receptor antagonists.
- To identify compounds with high affinity and selectivity for alpha(V)beta(3) and GPIIbIIIa receptors.
- To evaluate the functional activity of identified compounds on human smooth muscle cell migration.
Main Methods:
- Screening of a combinatorial library based on a biphenyl scaffold.
- Structure-Activity Relationship (SAR) studies to optimize compound potency and selectivity.
- In vitro assays to assess receptor binding and functional cell migration inhibition.
Main Results:
- Identification of compounds with subnanomolar activity against the vitronectin receptor.
- Demonstration of selectivity for the related GPIIbIIIa receptor.
- Confirmation of functional inhibition of human smooth muscle cell migration by lead compounds.
Conclusions:
- Novel biphenyl-based compounds are potent antagonists of the vitronectin receptor.
- These compounds exhibit desirable selectivity profiles and inhibit key processes in restenosis.
- Further development of these antagonists holds therapeutic potential for post-angioplasty restenosis.